NewAmsterdam Pharma Co N.V. 8-K

What Happened

• On February 18, 2026, NewAmsterdam Pharma Company N.V. announced corporate updates and reported its financial results for the year ended December 31, 2025 via a press release.
• The company filed a Form 8-K (Item 2.02) to furnish that press release, which is attached as Exhibit 99.1 to the filing. The 8-K was signed by Chief Financial Officer Ian Somaiya.

Key Details

• Filing date: February 18, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: Year ended December 31, 2025.
• Press release: Furnished as Exhibit 99.1 to the Form 8-K (dated February 18, 2026).
• Authorized signature: Ian Somaiya, Chief Financial Officer.

Why It Matters

• This 8-K is a timely disclosure that the company has publicly released its full-year 2025 earnings and corporate updates; investors should read the attached press release (Exhibit 99.1) for actual revenue, earnings, cash position, and any guidance or material developments.
• The Form 8-K itself does not replace detailed financial statements or MD&A — for deeper analysis, investors should review the press release, subsequent SEC filings (e.g., 10-K), and other investor communications for the specific financial results and context.